预计到 2028 年全球生物相似药市场的成长机会

提高获取、采用和认知度是生物相似药未来成长潜力的关键

在生物相似药製造商和法规机构的主导，随着患者和医疗保健专业人员对治疗的理解和认识不断提高，生物相似药的接受度和使用量正在增加。随着越来越多的资讯和实用资料可得性生物相似药的安全性和有效性，患者和医疗保健专业人员对它们的信心不断增强。製药公司必须巧妙地平衡保护自家公司生物製药和培育有利于生物相似药存在的环境之间的复杂平衡，这不可避免地有助于繁荣的竞争环境。

本研究介绍了全球生物相似药市场的整体状况以及按细分市场分類的收益预测。我们根据生物相似药市场参与企业的趋势、不断发展的商业模式以及各相关人员的策略必要事项来强调关键的成长机会。确定产生最多收益的治疗领域和产品类型。强调影响区域生物相似药采用和生物相似药市场进入的因素。此外，本报告还讨论了可能影响生物相似药渗透率的复杂要素，包括报销和付款人情况、生物相似药价格趋势和生物相似药销售趋势。该研究还讨论了行业问题，例如区域生物仿製药差异、医生招聘和专利诉讼。该报告确定了加速生物相似药普及和创新以及在神经病学和肿瘤学等新治疗领域竞争的关键成长机会。

目录

战略问题

• 成长为何困难
• The Strategic Imperative 8（TM）
• 战略要务对全球生物相似药市场的影响
• 成长机会是Growth Pipeline Engine（TM）

成长机会分析

• 分析范围
• 市场区隔
• 生物相似药市场的主要区域竞争
• 成长促进因素
• 成长抑制因素

生物相似药市场的成长环境

• 亮点 - 生物相似药的区域动态
• 成长机会 - 生物相似药市场
• 促进生物相似药开发和普及的策略
• 生物相似药-山德士主导生物相似药的普及
• 北美竞争基准化分析- 主要国家
• 市场概述—美国生物相似药市场
• 生物相似药在美国核准
• 美国医疗保健金融和配销通路
• 利用下一波生物相似药改变商业模式
• PBM 配方在提高生物相似药可及性方面的作用不断演变
• 不断变化的美国生物相似药法规环境
• 由于 IRA 反应，美国胰岛素生物相似药市场经历重大调整
• 美国的双重定价策略
• 美国癌症领域
• 美国癌症支持护理
• 美国免疫学/眼科
• 欧洲竞争基准化分析- 主要国家
• 市场概述– 欧洲生物相似药市场
• 生物相似药在欧洲核准
• 快速推出生物相似药—丹麦的成功故事
• 促进生物相似药采用的激励措施
• 亚太和中东/非洲竞争基准化分析- 主要国家
• 市场概述- 亚太地区、中东和非洲的主要生物相似药市场
• 亚洲生物製药和 CDMO 的全球市场日益受到关注

成长机会分析 - 生物相似药产业

• 主要成长指标
• 预测假设与考察- 生物相似药市场
• 收益预测 - 生物相似药全球市场
• 收益预测分析—全球生物相似药市场
• 按产品类型分類的收益预测
• 按产品类型分類的收益和预测分析
• 按治疗领域分類的收益预测
• 主要新型和即将推出的生技药品的专利到期
• 收益预测分析-肿瘤领域
• 收益预测分析 - 肌肉骨骼和免疫学
• 收益预测分析 - 内分泌及眼科
• 竞争环境
• 收益占有率
• 收益占有率分析

成长机会宇宙

• 成长机会 1：RWE 解决方案
• 成长机会2：神经生物相似药
• 成长机会三：聚焦中东与非洲
• 成长机会 4：人工智慧、PD 和组别生物标誌物的利用
• 成长机会 5：mAb 生物相似药的替代配方方法

下一步

Increasing Access, Adoption, and Awareness are the Key to Future Growth Potential of Biosimilars

Biosimilar acceptance and use are increasing as patients and healthcare providers improve their understanding and awareness of therapeutic agents driven by biosimilar manufacturers and regulators. As the availability of information and practical data supporting the safety and effectiveness of biosimilars increases, both patients and healthcare professionals are developing a greater level of confidence in these medications. It is imperative for pharmaceutical companies to delicately navigate the intricate balance between safeguarding their biologic products and cultivating an environment conducive to the presence of biosimilars, which inevitably contribute to a thriving competitive milieu.

This study presents overall market and segment-wise revenue forecasts for the global biosimilars market. It highlights key growth opportunities for biosimilar market participants based on the trends, evolution of business models, and strategic imperatives for various stakeholders. It identifies the greatest revenue-generating therapeutic areas and product types. The elements affecting regional biosimilar uptake and biosimilar market entrance have been clearly stated. In addition, this report covers complicated factors, including reimbursement and payer landscape, biosimilar price trends, and biosimilar sales trends that will affect biosimilar penetration. The study discusses regional biosimilar discrepancies as well as industry issues, including physician adoption and patent litigations. This report identifies key growth opportunities to increase biosimilar uptake and innovations and compete for newer therapy areas, such as neurology and oncology.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Global Biosimilars Market
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Market Segmentation
• Key Regional Competitors in the Biosimilars Market
• Growth Drivers
• Growth Restraints

Growth Environment-Biosimilars Market

• Highlights-Biosimilars Regional Dynamics
• Growth Opportunities-Biosimilars Market
• Strategies to Boost Biosimilars Development and Adoption
• Biopharma Taking Lead to Boost Adoption of Biosimilars-Sandoz
• North America Competitive Benchmarking-Key Countries
• Market Snapshot-US Biosimilar Market
• Biosimilars Approved in the US
• The US Healthcare Financial and Distribution Pathways
• Business Model Transformation due to the Next Wave of Biosimilars
• Evolving Roles of PBM Formularies to Boost Biosimilar Accessibility
• Evolving US Biosimilar Regulatory Landscape
• US Insulin Biosimilar Market Set for Major Reset in Response to IRA
• Dual Pricing Strategy in the US
• US Oncology
• US Oncology Supportive Care
• US Immunology and Ophthalmology
• Europe Competitive Benchmarking-Key Countries
• Market Snapshot-Europe Biosimilars Market
• Biosimilars Approved in Europe
• Swift and Rapid Adoption of Biosimilar-Denmark Success Story
• Incentives Driving Adoption of Biosimilars
• APAC and MEA Competitive Benchmarking-Key Countries
• Market Snapshot-Key APAC and MEA Biosimilar Market
• Intensifying Focus of Asian Biopharma and CDMO on the Global Market

Growth Opportunity Analysis-Biosimilars Industry

• Key Growth Metrics
• Forecast Assumptions and Considerations-Biosimilars Market
• Revenue Forecast-Global Biosimilars Market
• Revenue Forecast Analysis-Global Biosimilars Market
• Revenue Forecast by Product Type
• Revenue Forecast Analysis by Product Type
• Revenue Forecast by Therapeutic Area
• New and Upcoming Key Biologics Patent Expiration
• Revenue Forecast Analysis-Oncology
• Revenue Forecast Analysis-Musculoskeletal and Immunology
• Revenue Forecast Analysis-Endocrinology and Ophthalmology
• Competitive Environment
• Revenue share
• Revenue Share Analysis

Growth Opportunity Universe

• Growth Opportunity 1: RWE Solutions
• Growth Opportunity 2: Neurology Biosimilars
• Growth Opportunity 3: Focus on the Middle East and Africa
• Growth Opportunity 4: Leveraging AI, PD, and Omics Biomarkers
• Growth Opportunity 5: Alternative Formulation Methodology for mAb Biosimilars

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer